Antibody–drug conjugates as an emerging therapy in oncodermatology
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-262192
- Antibody–drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Such drugs consist in a monoclonal antibody linked to a cytotoxic agent, allowing a specific cytotoxicity to tumor cells. In recent years, tremendous progress has been observed in therapeutic approaches for advanced skin cancer patients. In this regard, targeted therapies (e.g., kinase inhibitors) or immune checkpoint-blocking antibodies outperformed conventional chemotherapy, with proven benefit toAntibody–drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Such drugs consist in a monoclonal antibody linked to a cytotoxic agent, allowing a specific cytotoxicity to tumor cells. In recent years, tremendous progress has been observed in therapeutic approaches for advanced skin cancer patients. In this regard, targeted therapies (e.g., kinase inhibitors) or immune checkpoint-blocking antibodies outperformed conventional chemotherapy, with proven benefit to survival. Nevertheless, primary and acquired resistances as well as adverse events remain limitations of these therapies. Therefore, ADCs appear as an emerging therapeutic option in oncodermatology. After providing an overview of ADC design and development, the goal of this article is to review the potential ADC indications in the field of oncodermatology.…
Autor(en): | Clara Esnault, David Schrama, Roland Houben, Serge Guyétant, Audrey Desgranges, Camille Martin, Patricia Berthon, Marie-Claude Viaud-Massuard, Antoine Touzé, Thibault Kervarrec, Mahtab Samimi |
---|---|
URN: | urn:nbn:de:bvb:20-opus-262192 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Cancers |
ISSN: | 2072-6694 |
Erscheinungsjahr: | 2022 |
Band / Jahrgang: | 14 |
Heft / Ausgabe: | 3 |
Aufsatznummer: | 778 |
Originalveröffentlichung / Quelle: | Cancers (2022) 14:3, 778. https://doi.org/10.3390/cancers14030778 |
DOI: | https://doi.org/10.3390/cancers14030778 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | antibody–drug conjugates; cutaneous T-cell lymphoma and Merkel cell carcinoma; melanoma; oncodermatology; skin squamous cell carcinoma |
Datum der Freischaltung: | 27.04.2023 |
Datum der Erstveröffentlichung: | 02.02.2022 |
Lizenz (Deutsch): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |